Fig. 1 · Structure

Documents & Downloads

Hypericin

Cat. No. A12069 CAS 548-04-9
Hypericin is a photosensitive antiviral, anticancer and antidepressant agent derived from Hypericum perforatum (St John's wort).

In Stock

Publications for Hypericin

2 publications citing this product

  1. Muhammad Ahsan Waqar, .et al. , ACS Omega, 2023, Oct 3;8(41):38191-38203 PMID: 37867680
  2. Booker A, .et al. , Phytomedicine, 2018, Feb 1;40:158-164 PMID: 29496168

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Hypericin photoactivation can produce lipid-peroxidation-associated cell injury. In A549 cells, hypericin-PDT lowered GSH and increased lipid oxidation, while liproxstatin-1 opposed these changes. Aggregate GPXs activity in cell lysates was not significantly reduced at 8 h. In HUCCT1 and CCLP1 cells, GPX4 overexpression rescued viability and reduced the PDT-induced ROS signal. These results support model-specific redox mechanisms rather than direct GPX4 enzyme inhibition. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Hypericin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Hypericin from 2 published references. In vitro models include human lung adenocarcinoma A549 cells; human lung adenocarcinoma A549 cells and lysates from treated cells.

Hypericin In Vitro Studies

Hypericin-PDT responses depend on the drug and light conditions. In A549 cells, liproxstatin-1 rescued viability after 2 μM hypericin with 2 min irradiation, but not after 125 nM with 30 min irradiation or 10 μM with 2 min irradiation. Pan-caspase inhibitor rescue in the low-concentration regime further limits a universal ferroptosis interpretation. [1]

Light-condition dependence of inhibitor rescue in A549 cells

Cell-based study · Human lung adenocarcinoma A549 cells [1]

Liproxstatin-1 rescued viability after the intermediate hypericin/light condition but not the lower-concentration/longer-light or higher-concentration conditions. Pan-caspase inhibitor rescue was seen in the low-concentration regime. These findings limit any single cell-death mechanism to its treatment context.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
A549 cell viability after hypericin/light with liproxstatin-1Qualitative inhibitor response Rescue at 2 μM/2 min; no rescue at 125 nM/30 min or 10 μM/2 min.[1]
A549 low-concentration phototoxicity with pan-caspase inhibitorQualitative rescue Z-VAD-FMK reduced cell death in the low-HYP concentration regime; inhibitors tested in Figure 1d had negligible effects at 2 μM/2 min.[1]

Literature-Reported Treatment Conditions

Treatment concentration
125 nM, 2 μM or 10 μM hypericin; liproxstatin-1 concentration-response comparison.
Exposure duration
4 h dark loading; irradiation 30 min for 125 nM, 2 min for 2 μM and 10 μM; viability typically 24 h after irradiation.
Method
Red light from xenon arc lamp, 600 nm band filter, 1.5 mW/cm²; CCK-8 viability normalized to DMSO vehicle.
Vehicle
DMSO; final concentration not specified in the read methods.
Co-treatment
Light activation; inhibitor cotreatments tested as mechanistic controls.
Reported limits
No IC50 estimated here; exact plotted percentages were not extracted.
Methods and source locations

Compound reported in the paper: Hypericin; Compound label in the paper: HYP

Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.

Results 1.1; Figure 1b–d,f–g; Methods 3.1–3.2, 3.19

A549 cell viability after hypericin/light with liproxstatin-1: CCK-8; viability measured typically 24 h post-light, three independent replicates; no graph-derived decimals. — Figure 1b; Results 1.1; Methods 3.2

A549 low-concentration phototoxicity with pan-caspase inhibitor: CCK-8; Figure 1c concentration series and Figure 1d intermediate-condition controls. — Figure 1c–d; Results 1.1

Lipid peroxidation and GPXs activity after hypericin photoactivation

Cell-based study · Human lung adenocarcinoma A549 cells and lysates from treated cells [1]

Under the 2 μM/2 min PDT condition, lipid oxidation increased and GSH decreased; liproxstatin-1 opposed these changes. A separate lysate readout within this redox assessment showed no significant decrease in aggregate GPXs activity at 8 h relative to control, unlike RSL3. The assay does not establish direct GPX4 inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lipid peroxidation and reduced glutathione after PDTDirectional redox response GSH decreased; MDA and C11-BODIPY oxidation increased; Lip-1 opposed these responses.[1]
Peroxide-reducing GPXs activity in A549 lysates 8 h after PDTStatistical comparison PDT versus control: ns; RSL3 reduced activity.[1]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM hypericin; liproxstatin-1 8 μM for Figure 2a,f–g; comparator RSL3 10 μM.
Exposure duration
4 h dark loading, 2 min red light; Figure 2a,f and S7b at 8 h post-light; Figure 2h follows lipid oxidation for 0–120 min.
Method
600 nm band-filtered xenon light, 1.5 mW/cm²; GSH assay, MDA assay, C11-BODIPY oxidation and lysate peroxide-reduction activity assay.
Vehicle
DMSO vehicle control; Figure 2b separately labels HYP-dark and HYP-PDT.
Co-treatment
Light activation; liproxstatin-1 and RSL3 used in specified comparison groups.
Reported limits
GPXs activity is an aggregate lysate readout, not an isolated purified GPX4 binding or enzyme-selectivity assay.
Methods and source locations

Compound reported in the paper: Hypericin; Compound label in the paper: HYP

Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.

Results 1.1–1.2; Figure 2a–b,f–h; Supplementary Figure S7b–c; Methods 3.2, 3.7–3.8, 3.10–3.11, 3.19

Lipid peroxidation and reduced glutathione after PDT: GSH/GSSG kit, MDA assay and C11-BODIPY flow cytometry; qualitative extraction only. — Figure 2a,f–h; Results 1.1–1.2; Methods 3.7, 3.10–3.11

Peroxide-reducing GPXs activity in A549 lysates 8 h after PDT: Lysate assay monitors NADPH absorption at 340 nm with cumene hydroperoxide substrate; S7b, mean ± SD, n=3 biologically independent samples. — Supplementary Figure S7b and caption; Methods 3.8; Results 1.1

GPX4 overexpression rescue of hypericin-PDT responses

Cell-based study · Human cholangiocarcinoma HUCCT1 and CCLP1 cells [2]

GPX4 overexpression opposed the reduction in viability and increased ROS signal caused by hypericin-PDT, relative to vector controls. This supports a GPX4-associated protective response in these cell lines without demonstrating direct hypericin binding to GPX4.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viability after HY-PDT in vector and GPX4-overexpressing cellsQualitative rescue GPX4 overexpression rescued viability in HUCCT1 and CCLP1 after hypericin-PDT.[2]
DCFH-DA ROS signal after HY-PDTQualitative rescue GPX4 overexpression reduced the PDT-induced ROS signal.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Rescue-panel hypericin concentration is not specified in the retrieved Figure 4E–F legend/Results; Figure 4A–D context uses 0, 1, 2 and 4 μM. All panels label HY-PDT at 1 J/cm².
Exposure duration
4 h dark loading; CCK-8 viability typically 24 h after irradiation.
Method
PBS wash after loading; 650 nm light, 1 J/cm²; vector versus GPX4-overexpression comparisons, CCK-8 and DCFH-DA fluorescence.
Vehicle
Hypericin vehicle not specified in the retrieved main methods.
Co-treatment
Light activation; GPX4 overexpression is a genetic rescue condition, not a second drug.
Reported limits
Hypericin concentration for Figure 4E–F, detailed transfection timing and ROS post-light collection time are not specified in the retrieved main text/legend. Do not borrow 2 μM from Figure 5. DCFH-DA is not lipid-peroxide-specific.
Methods and source locations

Compound reported in the paper: Hypericin; Compound label in the paper: HY

Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.

Results “HY-PDT triggers ferroptosis regulated by GPX4 in CCA cells”; Figure 4E–F (context A–D); Materials and methods reagent table, HY-PDT/viability and ROS methods

Viability after HY-PDT in vector and GPX4-overexpressing cells: CCK-8 absorbance at 450 nm; vector and overexpression-only controls included. — Figure 4E; associated Results; HY-PDT treatment and cell viability assay

DCFH-DA ROS signal after HY-PDT: Representative fluorescence images; no fluorescence magnitude inferred. — Figure 4F; associated Results; Reactive oxygen species detection

Hypericin In Vivo Studies

In a HUCCT1 xenograft model, intravenous hypericin at 4 or 8 mg/kg combined with red-light treatment inhibited tumor growth over a 10-day follow-up. The higher-dose regimen produced greater inhibition, and liproxstatin-1 partly opposed the response. Drug vehicles and separate control illumination were incompletely described, and the experiment did not include a dark hypericin arm. [2]

Hypericin-PDT in HUCCT1 xenograft-bearing mice

Animal study · Female BALB/c nude mice bearing subcutaneous HUCCT1 xenografts; 6 mice per randomized group [2]

Combined hypericin-PDT inhibited tumor growth during the reported 10-day follow-up. Inhibition was greater with 8 than 4 mg/kg hypericin and was partly opposed by liproxstatin-1. The design supports regimen-level activity, with limited attribution to hypericin alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serial xenograft tumor volumeQualitative tumor-growth comparison Hypericin-PDT inhibited growth in a dose-dependent pattern; Lip-1 partly reversed inhibition.[2]

Conditions shared by the study groups

Vehicle
Saline for control; drug vehicles not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline controlThis is the saline comparator group.Comparator for tumor-growth curves; control light exposure not separately explicit.[2]
Hypericin 4 mg/kg plus light
4 mg/kg
Saline group; no dark hypericin arm shown.Tumor growth lower than saline control.[2]
Hypericin 8 mg/kg plus light
8 mg/kg
Saline group; no dark hypericin arm shown.Greater tumor-growth inhibition than the 4 mg/kg regimen.[2]
Hypericin 8 mg/kg plus light and liproxstatin-1
8 mg/kg hypericin; 10 mg/kg liproxstatin-1
Saline group; no dark hypericin arm shown.Liproxstatin-1 partially counteracted tumor-growth inhibition.[2]
Saline control
Model: Female BALB/c nude mice with HUCCT1 xenografts; n=6 per group
Route: Injection; control route not separately specified.
Frequency: Equal-volume saline injection.
Treatment course: Tumor response followed for 10 days after irradiation.
Reported limits: Drug vehicles and separate control illumination status not specified; exact effect sizes not extracted.
Hypericin 4 mg/kg plus light
Model: Female BALB/c nude mice with HUCCT1 xenografts; n=6 per group
Route: Tail vein
Frequency: Single hypericin injection per Results; light at 4 h and 24 h per Methods.
Treatment course: Tumor response followed for 10 days after irradiation.
Reported limits: Drug vehicles and separate control illumination status not specified; exact effect sizes not extracted.
Hypericin 8 mg/kg plus light
Model: Female BALB/c nude mice with HUCCT1 xenografts; n=6 per group
Route: Tail vein
Frequency: Single hypericin injection per Results; light at 4 h and 24 h per Methods.
Treatment course: Tumor response followed for 10 days after irradiation.
Reported limits: Drug vehicles and separate control illumination status not specified; exact effect sizes not extracted.
Hypericin 8 mg/kg plus light and liproxstatin-1
Model: Female BALB/c nude mice with HUCCT1 xenografts; n=6 per group
Route: Tail vein; liproxstatin-1 intraperitoneally
Frequency: Single hypericin injection per Results; light at 4 h and 24 h per Methods.
Treatment course: Liproxstatin-1 24 h before irradiation, then once daily for first three days after irradiation; endpoint 10 days after irradiation.
Reported limits: Drug vehicles and separate control illumination status not specified; exact effect sizes not extracted.
Methods and source locations

Compound reported in the paper: Hypericin; Compound label in the paper: HY

Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.

Materials and methods “In vivo xenograft mouse study”; Results “HY-PDT triggers ferroptosis and inhibits CCA cells proliferation and EMT in vivo”; Figure 8A–B

Serial xenograft tumor volume: Volume = 0.5 × length × width²; n=6 mice per group; numerical variables reported as mean ± SD. No graph-derived volumes or percentage inhibition. — Figure 8A–B; In vivo xenograft mouse study; associated Results

Saline control · Figure 8A–B; In vivo xenograft mouse study; associated Results

Hypericin 4 mg/kg plus light · Figure 8A–B; In vivo xenograft mouse study; associated Results

Hypericin 8 mg/kg plus light · Figure 8A–B; In vivo xenograft mouse study; associated Results

Hypericin 8 mg/kg plus light and liproxstatin-1 · Figure 8A–B; In vivo xenograft mouse study; associated Results

Specifications

Manufacturer Adooq Bioscience
CAS Number 548-04-9
Formula C30H16O8
Molecular Weight 504.45
SMILES
CC1=CC(=C2C3=C1C4=C5C(=C(C=C4C)O)C(=O)C6=C(C=C(C7=C6C5=C3C8=C7C(=CC(=C8C2=O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 95 mg/mL (188.32 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hypericin Research References

  1. [1] Sufang Shui, Zenglu Zhao, Hao Wang, et al. Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway Redox biology (2021). PMID: 34229160 DOI: 10.1016/j.redox.2021.102056 Source material
  2. [2] Wei An, Kai Zhang, Guangbing Li, et al. Hypericin mediated photodynamic therapy induces ferroptosis via inhibiting the AKT/mTORC1/GPX4 axis in cholangiocarcinoma Translational oncology (2025). PMID: 39674093 DOI: 10.1016/j.tranon.2024.102234 Source material

Publications

2 publications citing this product

  1. Muhammad Ahsan Waqar, .et al. , ACS Omega, 2023, Oct 3;8(41):38191-38203 PMID: 37867680
  2. Booker A, .et al. , Phytomedicine, 2018, Feb 1;40:158-164 PMID: 29496168

Added to your cart

View Cart Checkout
Loading...